TELA TELA Bio Inc.

Medical Device Company
8.81
+0.2  (+2%)
Previous Close 8.61
Open 9
52 Week Low 7.23
52 Week High 16.5268
Market Cap $128,252,104
Shares 14,557,560
Float 6,295,911
Enterprise Value $111,001,240
Volume 17,493
Av. Daily Volume 18,481
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the first quarter ended March 31, 2022.

    Recent Highlights

    • Reported revenue of $8.2 million for the first quarter, representing growth of 40% over the corresponding period of 2021;
    • Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products in the first quarter of 2022, resulting in a year-over-year revenue increase for each product of approximately 21% and 111%, respectively;
    • Ended the first quarter…
    View Full Article
  2. MALVERN, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the 2022 H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.

    TELA Bio's management will be participating virtually in the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the live and archived webcast at ir.telabio.com on May 24, 2022, at 7am ET.

    About TELA Bio, Inc.

    TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology…

    View Full Article
  3. MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA approved inducement grants of stock options to purchase an aggregate of 50,950 shares of its common stock to 13 newly-hired employees, with a grant date of April 27, 2022 (the "Grant Date"). The stock options were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were…

    View Full Article
  4. MALVERN, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced the hiring of D. Taylor Ocasio as the Company's new General Counsel (GC). As GC, Mr. Ocasio will lead the Company's legal and governance efforts.

    Mr. Ocasio joins TELA with nearly ten years of corporate legal operations and healthcare industry experience. Most recently, Mr. Ocasio served as Deputy General Counsel of Zynerba Pharmaceuticals, a clinical-stage specialty pharmaceutical company, where he helped lead the legal functions…

    View Full Article
View All TELA Bio Inc. News